{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-003370","form_type":"8-K","ticker":"LFST","cik":"0001845257","company_name":"LifeStance Health Group, Inc.","filed_at":"2022-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.808657+00:00","generated_at":"2026-06-27T00:07:54.183717+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LifeStance Q4 revenue $190.1M (+61% YoY); net loss $108M; 2022 guidance reaffirmed","bullets":["Full-year 2021 revenue $667.5M (+77% YoY); net loss $307.2M largely from stock-based compensation.","Q4 Adjusted EBITDA $11.4M (6.0% of revenue), down 31% YoY; full-year Adjusted EBITDA $49.2M (7.4% of revenue).","Clinician base grew 55% to 4,790; 415 net adds in Q4 and 1,693 for the full year.","2022 guidance: revenue $865-885M, Center Margin $240-255M, Adjusted EBITDA $63-67M.","Q1 2022 revenue expected $195-200M; Omicron impact estimated at $3-7M; de novo openings moderated to 80-90."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-003370","json":"https://secwatch.observer/filing/0000950170-22-003370.json","markdown":"https://secwatch.observer/filing/0000950170-22-003370.md","text":"https://secwatch.observer/filing/0000950170-22-003370.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1845257/000095017022003370/0000950170-22-003370-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1845257/000095017022003370/lfst-20220310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:07:54.183717+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}